Last reviewed · How we verify
DSM265 xmg
DSM265 is a dihydroorotate dehydrogenase (DHODH) inhibitor.
DSM265 is a dihydroorotate dehydrogenase (DHODH) inhibitor. Used for Malaria.
At a glance
| Generic name | DSM265 xmg |
|---|---|
| Sponsor | Medicines for Malaria Venture |
| Drug class | DHODH inhibitor |
| Target | DHODH |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
DHODH is an enzyme involved in the de novo pyrimidine synthesis pathway. Inhibiting DHODH can lead to a decrease in the production of pyrimidine nucleotides, which are essential for DNA replication and cell division. This can be particularly effective against malaria parasites, which rely heavily on this pathway for survival.
Approved indications
- Malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |